13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q2 2025 · Filed August 14, 2025 · Accession 0000950123-25-008422
Total Value
$461.4M
Positions
13
Other Managers
0
Confidential Omitted
No
Holdings (13)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Arcellx, Inc. | ACLX | 2,346,630 | $154.5M | 33.49% |
| 2 | ARS Pharmaceuticals, Inc. | SPRY | 4,012,903 | $70.0M | 15.18% |
| 3 | CRISPR Therapeutics AG | CRSP | 1,048,951 | $51.0M | 11.06% |
| 4 | Zenas BioPharma, Inc | ZBIO | 4,911,539 | $47.6M | 10.32% |
| 5 | ORIC Pharmaceuticals, Inc. | ORIC | 4,514,929 | $45.8M | 9.93% |
| 6 | Mineralys Therapeutics Inc. | MLYS | 3,127,933 | $42.3M | 9.17% |
| 7 | Design Therapeutics, Inc. | DSGN | 6,526,476 | $22.0M | 4.77% |
| 8 | Oculis Holding AG | OCSAW | 322,500 | $6.3M | 1.36% |
| 9 | Alumis Inc. | ALMS | 1,959,896 | $5.9M | 1.27% |
| 10 | Nkarta, Inc. | NKTX | 3,333,333 | $5.5M | 1.20% |
| 11 | Oruka Therapeutics, Inc | ORKA | 430,330 | $4.8M | 1.05% |
| 12 | KALA Bio, Inc. | KALA | 598,940 | $2.9M | 0.62% |
| 13 | enGene Holdings Inc. | ENGNW | 747,750 | $2.7M | 0.59% |